treatment of myelodysplastic syndrome
All entries for: Ascentage Pharma Group, Inc.
January 15, 2026
Ascentage Pharma Group, Inc.
Orphan Drug Designation
Disease Area: Rare Disease
treatment of myelodysplastic syndrome